Evonik
Leading Beyond Chemistry

Q3 2026 Results

November 3, 2026

Dr. Claus Rettig, Interim Chief Executive Officer

Michael Rauch, Chief Financial Officer

EVONIK
Leading Beyond Chemistry

Strong financial performance with Q3 delivered as guided …
… coupled with disciplined strategy execution

Continued strong operating performance in Q3 2026 as guided	**€629 m** (+40% yoy) adj. EBITDA in Q3	**16.4%** (+3.2pp yoy) adj. EBITDA margin in Q3
Delivering standout cash conversion and deleveraging	**€601 m** (doubled yoy) FCF after 9M	**2.1x** (vs. 2.5x yoy) total leverage end of Sep
FY 2026 adj. EBITDA guidance specified: Confident to achieve upper half of range	**Upper half** of €2-2.2 bn adj. EBITDA range	**~€850 m** FCF (40% conversion)
ROCE guidance upgraded – good progress towards ~11% target by 2029	**>8%** (2025: 6.1%) ROCE in FY 2026	**~11%** ROCE by 2029

EVONIK
Leading Beyond Chemistry

Clearly defined strategy to deliver attractive shareholder return



EVONIK – LEADING BEYOND CHEMISTRY

Tailored solutions and industrial excellence

Leading Portfolio	+	Sustainable Innovation	+	Regional Balance	+	Team Excellence	=	Shareholder Return
We are best positioned for the future, after a profound transformation		*We are leveraging sustainable innovation as major growth-driver*		*We are striving for a regionally balanced footprint*		*We are engaged as a team*		*We are committed to consistent and attractive returns for our shareholders*
…with our leading portfolio structured in two distinct, complementary business models under one roof		…with Next Generation Solutions, process innovation (Next Generation Technologies) and our three Innovation Growth Areas		…targeting an equal sales distribution across all regions; our local-for-local approach is ensuring supply security and cost competitiveness		…delivering on our promises, executing on our strategy, even succeeding in a continued tough environment		…through disciplined capital allocation, focused on organic growth and an attractive dividend

EVONIK
Leading Beyond Chemistry

Table of contents


1 Our path to ~11% ROCE by 2029

2 Highlights Q3 2026 and Outlook 2026

3 Financial performance Q3 2026

EVONIK
Leading Beyond Chemistry

Our path to ~11% ROCE by 2029 is underpinned by tangible strategic levers – at the same time driving up earnings and reducing capital employed



1. Adj. EBIT / Capital Employed

EVONIK
Leading Beyond Chemistry

1 Growth: Sustainable innovation as long-term sales and earnings driver


Evonik Innovation Growth Areas



€1.5 bn additional sales by 2032[1] at >20% margin

Advance Precision Biosolutions	Enable Circular Economy	Accelerate Energy Transition

Expanding into fast growing end markets[2]



Biosurfactants

- From cleaning to cosmetics and industrial applications

~20%



ROHACELL®

Lightweight materials

- Foams used in wings, blades and radomes
- Now also for drones

>15%



AEROXIDE®

Batteries

- High-performance aluminum oxide grades for lithium-ion-batteries

>10%

1. vs. year-end 2023 | 2. Expected market growth: CAGR 2024-2030

EVONIK Leading Beyond Chemistry

1 Growth: Investing into Custom Solutions
Evonik launches new projects in additives and biotechnology

Siloxane capacity expansion for PU[1] foam and coating additives

New GMP[2] facility for lipid-based drug delivery systems

Biotechnology expansion project for drug substance contract manufacturing

Accelerate Growth



~€50 m invest in Essen (Germany)



>€50 m invest in Vancouver (Canada)



~€80 m invest in Slovenská Ľupča (Slovakia)

1. Polyurethane | 2. Good Manufacturing Practice

EVONIK Leading Beyond Chemistry

2 Efficiency: Organization tailored to our businesses needs leading to more agility and tight cost control

Evonik Tailor Made

Phase 1
2024 – 2026

- Reorganization "Evonik Tailor Made"
- Business optimization
- Procurement optimization

Phase 2
2027 – 2029

Holistic approach:
Integrated optimization program across administration and businesses

Launching now!

Organization in 2029

- Empowered businesses and faster decision-making
- Reduced complexity and rightsized organization
- Cost base under control
- Fully aligned with employee representatives

EVONIK Leading Beyond Chemistry

2 Efficiency: ETM phase two integrates decisive business optimization measures

Operational excellence	Improved raw material sourcing	Asset network optimization	Portfolio focus shift
▪ **Review business models** according to market position ▪ Increase **sales force effectiveness** / profit enhancement initiative ▪ **Synergetic** business line **mergers**	▪ **Backward integration** in Mobile (Methionine) ▪ **Optimization of raw material purchasing**	▪ **Site consolidation:** closure of smaller/ older sites ▪ **Production transfer** to larger production hubs to increase capacity utilization and ensure business continuity	▪ Continuous **portfolio transformation** within each Business Line including discontinuation of selected product groups and closure of associated production plants

Progress in 2026 so far (examples)

✓ Strong volume development and profit enhancement in High Performance Polymers	✓ Backward integration in Mobile (Methionine) up and running	✓ Active site consolidation and optimization in Silica and Crosslinkers	✓ Announced exit of polyester business incl. closure of Witten site

EVONIK Leading Beyond Chemistry

3 Portfolio change: Focusing on our strong core by executing major divestments

Evonik core





Innovation-driven businesses with **tailored and science-based solutions**

Efficiency-driven businesses with a **high level of technological expertise** and **operational excellence**

Divestments



SYNEQT


Oxeno divestment firmly on track, aiming for signing in the coming months

Best owner process for SYNEQT to be launched immediately after Oxeno signing

EVONIK Leading Beyond Chemistry

4 Capex: Sustainable reduction in capital intensity thanks to a structural shift in our investment approach

Capex vs. adj. D&A (in € m)



Structural shift in investment approach enabling sustainably lower capex

From…

- Large-scale projects across all businesses
- High asset-intensity
- Large single-project investments

To…

- Additives and biotechnology focus
- Lower asset-intensity
- Small-sized, fast return projects
- 50 : 50 growth vs maintenance capex

EVONIK Leading Beyond Chemistry

5 Net working capital: AI-enabled tighter control reducing capital employed

Today: ~18% NWC to sales ratio with significant optimization efforts towards year-end



Optimization of inventory

- AI-enhanced forecasting (IBP)
  - → Better demand planning
  - → Lower safety stocks
  - → Reduced inventory levels



Optimization of accounts receivables/ accounts payables

- Automated invoicing and streamlined administrative processes accelerated by digitalization
  - → Faster cash conversion

Target: NWC to sales ratio of ~17% with improved balance throughout the year

EVONIK Leading Beyond Chemistry

Table of contents

1 Our path to ~11% ROCE by 2029


2 Highlights Q3 2026 and Outlook 2026

3 Financial performance Q3 2026

EVONIK
Leading Beyond Chemistry

Continued strong operating performance in Q3: Adj. EBITDA of €629 m (+40% yoy) and 16.4% margin (+3.2pp)

Adj. EBITDA (in € m) / Margin (in %)



Drivers of Q3 performance


- Solid performance in **Custom Solutions** (+7% yoy)
- Exceptional quarter for **Advanced Technologies** (+87% yoy)
  - Strong demand in High Performance Polymers – unrelated to global supply chain disruptions
  - Strong pricing in Crosslinkers and Animal Nutrition
- **Infrastructure** (+48% yoy) driven by higher spreads and margins in **Oxeno** (C4) business
- Earnings support from **optimization programs** across the Group

EVONIK Leading Beyond Chemistry


Free Cash Flow after nine months more than doubled vs. last year's level – well on track for 40% cash conversion rate in FY 2026

Free Cash Flow (in € m)

Q3



9M




Supporting factors for strong FCF

- FCF after nine months >€300 m ahead of last year resulting in significant deleveraging
- Strong operating performance as basis: Adj. EBITDA +14% yoy after nine months
- Strict NWC management and tight control of capex budget
- Lower bonus cashout

EVONIK
Leading Beyond Chemistry

Confident to achieve upper half of guidance range for FY 2026 of adj. EBITDA of €2.0 - 2.2 bn

Adj. EBITDA (in € bn)



Drivers for Q4 adj. EBITDA


- FY guidance (“upper half of range”) implies **solid yoy earnings growth also in Q4**
- Good finish to a very strong year expected
- Order books continue to look healthy

- Q4 with usual seasonality
- Raw material and energy costs on the rise
- Methionine prices normalizing vs exceptionally strong Q3

EVONIK
Leading Beyond Chemistry

Confident to achieve a cash conversion rate of 40% – implying FCF of ~€850 m for FY 2026

Free Cash Flow (in € m) / **Conversion rate**[1] (in %)



Cash generation aligned w/ capital allocation priorities

Disciplined investments into growth:
Tight capex budget of ~€750 m in 2026
sufficient to drive focused growth initiatives

Payment of attractive dividend
within new payout corridor
of 40-60% of adj. net income

De-leveraging visible – rating upgrade secured:
Net financial debt -€400 m yoy; total leverage 2.1x
Moodys rating upgraded to Baa1


1. Cash Conversion Rate = FCF / adj. EBITDA

EVONIK
Leading Beyond Chemistry

We execute on our strategy with full force – building a focused, more agile company with ~11% ROCE by 2029

We drive earnings growth	We tightly manage our capital base	We optimize our portfolio
Growth investments	Sustainably lower capex	Oxeno & SYNEQT
Efficiency gains	Tight NWC management	Smaller divestments

Basis: Strong operating performance 2026



EVONIK
Leading Beyond Chemistry

Table of contents

1 Our path to ~11% ROCE by 2029

2 Highlights Q3 2026 and Outlook 2026

3 Financial performance Q3 2026

EVONIK
Leading Beyond Chemistry

Q3 2026 results overview

Sales (in € m)

3,825

(Q3 2025: 3,391)

Sales (yoy)

Volume	Price
+2%	+10%
FX	**Other**
+/-0%	+1%

Adj. EBITDA (in € m)

629

(Q3 2025: 448)

Capex[1] (in € m)

193

(Q3 2025: 181)

Free Cash Flow (in € m)

369

(Q3 2025: 300)

Adj. EPS (in €)

0.71

(Q3 2025: 0.27)

1. Cash outflows for investments

EVONIK
Leading Beyond Chemistry

Custom Solutions

Sales
(in € m)


Additives


Care

Adj. EBITDA
(in € m)
/ margin
(in %)

Q3 26 vs. Q3 25

Volume	Price	FX	Other
+/-0%	+5%	+/-0%	-1%





Additives (adj. EBITDA up yoy)

- Solid sales (+6%) and earnings growth vs. prior year, mainly driven by stronger oil and coating additives as well as catalyst businesses
- Compared to Q2 slight sales and earnings decline reflecting seasonal summer dip, plus some normalisation after supply chain-related pre-buying

Care (adj. EBITDA stable yoy)

- Flat sales and earnings development compared to prior year on overall rather subdued level
- Care Solutions with higher prices not fully compensating higher input costs; specialties doing well; stabilizing volumes on low level in base ingredients
- Health Care with higher demand in oral and parenteral drug delivery, good pricing and enhanced plant effectiveness

EVONIK
Leading Beyond Chemistry

Advanced Technologies

Sales
(in € m)

Inorganics


Organics


Animal Nutrition

Adj. EBITDA
(in € m)
/ margin
(in %)

Q3 26 vs. Q3 25

Volume	Price	FX	Other
+4%	+14%	+/-0%	+1%





Inorganics (adj. EBITDA up yoy)
- Silica benefits from network optimization; positive volume development driven by oral care and specialties
- Hydrogen peroxide stable on (weak) prior-year level


Organics (adj. EBITDA up yoy)
- High Performance Polymers benefitting from strong volume development (= higher plant utilization) – demand improvement unrelated to supply chain disruptions
- Crosslinkers capitalizing on market momentum and with improved plant availability vs. prior year

Animal Nutrition (adj. EBITDA up yoy)
- Continued strong earnings momentum driven by significantly higher prices
- Volume recovery towards the end of the quarter following a slight summer dip
- Backward integration in the US now fully operational


EVONIK
Leading Beyond Chemistry

Infrastructure / Other

Adj. EBITDA (in € m)



Thereof: Infrastructure



- Oxeno (C4): still benefiting from higher margins due to supply chain disruptions associated with Middle East conflict, but below very strong Q2 levels
- Infrastructure: as usual high level of stability and benefiting from saving programs

Thereof: Other



- Higher cost savings not fully compensating further increased bonus provisions for FY 2026

EVONIK Leading Beyond Chemistry


EVONIK
Leading Beyond Chemistry

Additional indications for FY 2026

Sales	**Around €15 bn** (unchanged; 2025: €14.1 bn)
ROCE	**Considerably above prior-year level: >8%** (previously: slightly above prior-year level; 2025: 6.1%)
Capex[1]	**Around €750 m** (unchanged; 2025: €748 m)
EUR/USD sensitivity[2]	+/-1 USD cent = -/+ ~€5 m adj. EBITDA (FY basis)
Adj. D&A	**Slightly below prior-year level** (unchanged; 2025: €1,013 m)
Adj. net financial result	**Around prior-year level** (unchanged; 2025: -€162 m)
Adj. tax rate	**Around 20%** (previously: ~25%; 2025: 22%)

1. Cash outflow for investment in intangible assets, pp&e | 2. Including transaction effects (after hedging) and translation effects; before secondary / market effects

EVONIK
Leading Beyond Chemistry

Adjusted income statement Q3 2026

in € m	Q3 2025	Q3 2026	Δ
Sales	**3,391**	**3,825**	13%
Adj. EBITDA	**448**	**629**	40%
Depreciation & amortization	-251	-240	
Adj. EBIT	**197**	**389**	98%
Adj. net financial result	-52	-61	
D&A on intangible assets	33	31	
Adj. income before income taxes	**178**	**359**	102%
Adj. income tax	-46	-26	
Adj. income after taxes	**132**	**333**	152%
Adj. non-controlling interests	4	3	
Adj. net income	**128**	**330**	158%
Adj. earnings per share (in €)	**0.27**	**0.71**	
Adjustments	-222	-395	

Adj. net financial result (-€61 m)

- Slightly more negative yoy due to higher interest expense

Adj. tax rate (7%)

- Low adj. tax rate driven by a favorable geographical earnings mix
- Resulting in lower projection for FY adj. tax rate (~20%)

Adjustments (-€395 m)

- -€313 m for restructuring, esp. provisions for second phase of Evonik Tailor Made
- -€80 m other special items: asset impairments in Care, Organics (-€264 m), partly offset by write-up in Animal Nutrition (+€187 m)

EVONIK Leading Beyond Chemistry

Cash flow statement Q3 2026

in € m	Q3 2025	Q3 2026
Income before financial result and income taxes (EBIT)	**-25**	**-6**
Depreciation and amortization	428	317
Δ Net working capital	79	-169
Change in provisions for pensions & other post-employment benefits	-28	-6
Change in other provisions	40	394
Change in miscellaneous assets/liabilities	7	60
Cash inflows/outflows from income taxes	-25	-31
Others	5	3
Cash flow from operating activities	**481**	**562**
Cash outflows for investment in intangible assets, pp&e	-181	-193
FCF	**300**	**369**
Cash flow from investing activities	**-14**	**-187**
Cash flow from financing activities	**-385**	**-237**

CF from operating activities

- Net working capital impacted by inventory build-up
- Higher other provisions driven by restructuring measures (esp. phase two of Evonik Tailor Made)

CF from investing activities


- Prior year benefited from sale of securities

CF from financing activities

- Lower outflow due to significantly reduced debt repayments


EVONIK Leading Beyond Chemistry

Net financial debt development Q3 2026



EVONIK
Leading Beyond Chemistry

Development of debt and leverage over time



Net financial debt (€3,292 m)

- Net financial debt slightly decreased
- Total leverage reduced to 2.1x, supported by lower net financial debt and higher LTM adjusted EBITDA

Pension provisions (€1,390 m)

- Pension provisions further reduced, mainly due to higher discount rates
- German pension discount rate increased to 4.7%

1. (Net financial debt – 50% hybrid bond + pension provisions) / Adj. EBITDA (LTM); 2. (Net financial debt – 50% hybrid bond) / Adj. EBITDA (LTM)

EVONIK
Leading Beyond Chemistry

Segment overview by quarter

Sales (in € m)	Q1/25	Q2/25	Q3/25	Q4/25	FY 2025	Q1/26	Q2/26	**Q3/26**
Custom Solutions	1,427	1,367	1,340	1,358	5,492	1,334	1,422	**1,394**
Advanced Technologies	1,601	1,511	1,445	1,416	5,973	1,450	1,647	**1,713**
Infrastructure / Other[1]	749	621	606	628	2,604	643	824	**718**
Evonik Group	3,777	3,499	3,391	3,402	14,069	3,427	3,893	**3,825**

Adj. EBITDA (in € m)	Q1/25	Q2/25	Q3/25	Q4/25	FY 2025	Q1/26	Q2/26	**Q3/26**
Custom Solutions	256	254	215	184	909	227	271	**231**
Advanced Technologies	291	266	202	185	944	241	333	**377**
Infrastructure / Other[1]	-13	-11	31	-12	21	7	26	**21**
Evonik Group	560	509	448	357	1,874	475	630	**629**

1. Including Oxeno (C4 business)

EVONIK
Leading Beyond Chemistry

Upcoming IR events

Conferences & roadshows

November 4, 2026	CFO Analyst Breakfast, London
November 4, 2026	Roadshow, London (Jefferies)
November 5, 2026	Virtual Roadshow (Berenberg)
November 9, 2026	Roadshow, Frankfurt (Berenberg)
November 11, 2026	European Conference, London (UBS)
November 11, 2026	Global Chemicals Conference, Boston (Morgan Stanley)
November 12, 2026	Roadshow, Montreal (Baader)
November 17, 2026	Roadshow, Zürich (Deutsche Bank)
November 17, 2026	Roadshow, Dublin (ODDO BHF)
November 23, 2026	Sustainable Future Forum, online (Barclays)
November 23, 2026	Deutsches Eigenkapitalforum, Frankfurt (Deutsche Börse)
December 2, 2026	BofA Chemicals Conference, London (Bank of America)

Upcoming reporting dates & events

March 4, 2027	Q4/FY 2026 Reporting
May 4, 2027	Q1 2027 Reporting
June 3, 2027	Annual General Meeting
August 4, 2027	Q2 2027 Reporting
November 4, 2027	Q3 2027 Reporting

EVONIK
Leading Beyond Chemistry

Evonik Investor Relations Team



Christoph Finke
Senior Vice President Investor Relations

+49 174 9931647
christoph.finke@evonik.com



Cédric Schupp
Director Investor Relations & ESG

+49 173 2552453
cedric.schupp@evonik.com



Katharina Gayk
Specialist Investor Relations

+49 174 9931669
katharina.gayk@evonik.com



Johanna Göbel
Director Investor Relations

+49 172 5268167
johanna.goebel@evonik.com



Janine Göttel
Specialist Investor Relations

+49 151 53831578
janine.goettel@evonik.com



Gevitha Selvakumar
Senior Manager Investor Relations & ESG

+49 174 9080817
gevitha.selvakumar@evonik.com

EVONIK
Leading Beyond Chemistry

Disclaimer

In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

EVONIK
Leading Beyond Chemistry


EVONIK
Leading Beyond Chemistry